AIMLogo.jpg
Hemispherx Biopharma Wins Federal Lawsuit Regarding Investment Banking Fees
March 10, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, March 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"or "Hemispherx"), announced that after more than a week in trial, a federal jury in Atlanta...
AIMLogo.jpg
A Clinical Update on the Search for a Universal Flu Vaccine: Presentation in Washington, DC on January 30, 2014 in Conjunction With the American Society for Microbiology (ASM) Biodefense Conference
January 28, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the ASM Biodefense Meeting is scheduled for January 27-29, 2014 at the Washington Marriott...
AIMLogo.jpg
Hemispherx Analysis of New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
January 22, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21,...
AIMLogo.jpg
Hemispherx Presents New Data on Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus
January 21, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 21, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced that Dr. William M. Mitchell of Vanderbilt University will present a research paper on January 21,...
AIMLogo.jpg
Hemispherx Biopharma to Present on January 15 at the Biotech Showcase Held in Conjunction With the 32nd JP Morgan Healthcare Conference in San Francisco
January 13, 2014 08:00 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced it will make a presentation at the Biotech Showcase held in conjunction with the 32nd JP Morgan...
AIMLogo.jpg
Hemispherx Biopharma Reports Evidence Based Clinical Potential of a Natural Interferon (IFN) -- Alpha for Infection Control and Treatment of Drug Resistant H7N9 Influenza Virus
January 07, 2014 08:30 ET | AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced publication of an article entitled "Emergence of a novel drug...
Centers for Disease Control Urges Preparation for an Active Seasonal Flu Season
December 16, 2013 08:30 ET | Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 16, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announced that the company will accelerate its experimental program for a new...
Noble Expands Into Global Biologics Market With Multisensory Device Training
August 07, 2013 09:15 ET | Noble
ORLANDO, FL--(Marketwired - Aug 7, 2013) -  Noble®, the leader in the design and manufacturing of training devices, is expanding its services to the global biologics market, offering...
China Investing Billions in Bid to Catch Up With Western Pharma
July 11, 2013 07:30 ET | Lux Research
BOSTON, MA--(Marketwired - Jul 11, 2013) - China's biomedical sector is rapidly transforming itself from a manufacturing base to an innovation hub, investing billions of dollars and setting up...
Pelican Continues Enhancement of Cold Chain Industry -- Acquires Renowned Minnesota Thermal Science, the Industry Leader of Temperature Controlled Transportation Products
January 14, 2013 13:20 ET | Pelican Products, Inc.
TORRANCE, CA--(Marketwire - Jan 14, 2013) - Pelican Products, Inc., the leader in the design and manufacture of high-performance protective case solutions and advanced portable lighting...